Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 118.88% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 15.00M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 15.00M.
Undervalued
The company’s latest PE is -22.82, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 150.25M shares, increasing 7.40% quarter-over-quarter.
Held by Lee Ainslie
Star Investor Lee Ainslie holds 1.85M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.37.